Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company anticipates a significant revenue increase due to strong adoption of PAPZIMEOS, supported by a permanent J-code, and geographic expansion plans. Despite regulatory and strategic risks, the optimistic guidance and expected cash flow breakeven by 2026 indicate a positive outlook. The lack of financial details in the call is offset by the promising strategic initiatives and market trends.
Key Financial Performance
Approval of PAPZIMEOS Approved in August 2025 as a novel first-line standard of care treatment for adults with RRP. No year-over-year change or financial figures provided in this excerpt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Approval of PAPZIMEOS: PAPZIMEOS was approved in August 2025 as a novel first-line standard of care treatment for adults with RRP. Significant progress has been made in the nine months since its launch.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges risks and uncertainties in forward-looking statements, which could cause actual results to differ materially. This implies potential regulatory hurdles or compliance challenges.
Strategic Execution Risks: The launch of PAPZIMEOS as a novel treatment for RRP is a significant milestone, but its success depends on effective execution and market adoption, posing a strategic risk.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Approval of PAPZIMEOS: The approval of PAPZIMEOS in August of 2025 has brought a novel first-line standard of care treatment for adults with RRP. In nine short months, we have witnessed tremendous progress with the first commercial therapeutic launch.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Chief
CEO Director
CFO COO
COO remark
Chief Financial
Citizens JMP
Co LLC
Conference Instructions
Director Chief
Division PM
Division afternoon
Dr approval
EDT Swayampakula
Financial Officer
Head Investor
Instructions Wednesday
Jason Butler
LLC Research
Mr sir
Officer CFO
Officer Chief
Officer Jason
PAPZIMEOS line
PM EDT
RRP month
Relations President
Relations today
Research Division
Update Conference
VP Head
Wednesday conference
conference Mr
line standard
month progress
sir VP
statement Dr
today update
PGEN Transcript
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Positive5-13
The company anticipates a significant revenue increase due to strong adoption of PAPZIMEOS, supported by a permanent J-code, and geographic expansion plans. Despite regulatory and strategic risks, the optimistic guidance and expected cash flow breakeven by 2026 indicate a positive outlook. The lack of financial details in the call is offset by the promising strategic initiatives and market trends.
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call highlights strong financial performance with a 149% revenue increase, despite a net loss due to non-recurring items. The Q&A reveals positive progress in patient conversion and treatment completion, and management's optimism about the European market. The J-code is expected to enhance patient processing, and the revenue guidance is clear. While there is uncertainty about European approval timing, the overall sentiment is positive, driven by strong revenue growth and operational improvements.
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary and Q&A reveal positive aspects: expansion plans, optimistic guidance on reaching cash breakeven, and strong market momentum for PAPZIMEOS. Despite some risks like cold chain logistics and regulatory compliance, the company’s financial health is stable with $123.6 million in cash and investments. The Q&A reassures on patient reimbursement and market adoption. The stock price is likely to react positively in the short-term, driven by optimistic guidance and market expansion strategies.
PGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
